A citation-based method for searching scientific literature

Margaret T Behme, John Dupré, Thomas J McDonald. BMC Endocr Disord 2003
Times Cited: 53







List of co-cited articles
562 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
J Dupre, M T Behme, I M Hramiak, P McFarlane, M P Williamson, P Zabel, T J McDonald. Diabetes 1995
121
37

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
John Dupré, Margaret T Behme, Thomas J McDonald. J Clin Endocrinol Metab 2004
92
32






Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.
Graydon S Meneilly, Christopher H S McIntosh, Raymond A Pederson, Joel F Habener, Mario R W Ehlers, Josephine M Egan, Dariush Elahi. Diabetes Care 2003
28
32


Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
Loredana Farilla, Angela Bulotta, Boaz Hirshberg, Sergio Li Calzi, Nasif Khoury, Houtan Noushmehr, Cristina Bertolotto, Umberto Di Mario, David M Harlan, Riccardo Perfetti. Endocrinology 2003
473
16

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Holst. J Clin Endocrinol Metab 2003
363
16



Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
15

The glucagon-like peptides.
T J Kieffer, J F Habener. Endocr Rev 1999
753
15



Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Michael A Nauck, Markus M Heimesaat, Kai Behle, Jens J Holst, Markus S Nauck, Robert Ritzel, Michael Hüfner, Wolff H Schmiegel. J Clin Endocrinol Metab 2002
402
15


Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Orville G Kolterman, John B Buse, Mark S Fineman, Eling Gaines, Sonja Heintz, Thomas A Bicsak, Kristin Taylor, Dennis Kim, Maria Aisporna, Yan Wang,[...]. J Clin Endocrinol Metab 2003
421
15

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
940
15



Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
C M Edwards, S A Stanley, R Davis, A E Brynes, G S Frost, L J Seal, M A Ghatei, S R Bloom. Am J Physiol Endocrinol Metab 2001
352
13


A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
13

Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.
N Imeryüz, B C Yeğen, A Bozkurt, T Coşkun, M L Villanueva-Peñacarrillo, N B Ulusoy. Am J Physiol 1997
261
13




Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
Christopher H S McIntosh, Hans-Ulrich Demuth, J Andrew Pospisilik, Raymond Pederson. Regul Pept 2005
115
13

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
184
11

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.
D A Stoffers, T J Kieffer, M A Hussain, D J Drucker, S Bonner-Weir, J F Habener, J M Egan. Diabetes 2000
453
11

Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
706
11


The incretin concept today.
W Creutzfeldt. Diabetologia 1979
650
11

Glucagon-like peptide-1: a potent regulator of food intake in humans.
J P Gutzwiller, B Göke, J Drewe, P Hildebrand, S Ketterer, D Handschin, R Winterhalder, D Conen, C Beglinger. Gut 1999
412
11

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
920
11

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
M B Toft-Nielsen, M B Damholt, S Madsbad, L M Hilsted, T E Hughes, B K Michelsen, J J Holst. J Clin Endocrinol Metab 2001
615
11


Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
Mark S Fineman, Thomas A Bicsak, Larry Z Shen, Kristin Taylor, Eling Gaines, Amanda Varns, Dennis Kim, Alain D Baron. Diabetes Care 2003
264
11

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Claus B Juhl, Malene Hollingdal, Jeppe Sturis, Grethe Jakobsen, Henrik Agersø, Johannes Veldhuis, Niels Pørksen, Ole Schmitz. Diabetes 2002
215
11

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.
A Wettergren, B Schjoldager, P E Mortensen, J Myhre, J Christiansen, J J Holst. Dig Dis Sci 1993
529
11

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
J Schirra, K Sturm, P Leicht, R Arnold, B Göke, M Katschinski. J Clin Invest 1998
192
11


NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE.
N MCINTYRE, C D HOLDSWORTH, D S TURNER. Lancet 1964
562
11

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Robert J Heine, Luc F Van Gaal, Don Johns, Michael J Mihm, Mario H Widel, Robert G Brodows. Ann Intern Med 2005
600
11

Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
R Lugari, C Dell'Anna, D Ugolotti, A Dei Cas, A L Barilli, R Zandomeneghi, B Marani, M Iotti, A Orlandini, A Gnudi. Horm Metab Res 2000
57
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.